Alaunos Therapeutics(TCRT) - 2022 Q1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For Q1 2022, Alaunos reported a net loss of approximately $9.8 million or $0.05 net loss per share, compared to a net loss of approximately $21.6 million or $0.10 net loss per share for Q1 2021, indicating a significant improvement in financial performance [14] - Research and Development expenses decreased to approximately $5.6 million in Q1 2022 from approximately $13.3 million in Q1 2021, a reduction of 58% [14] - General and Administrative expenses also decreased to approximately $3.5 million in Q1 2022 from approximately $8.2 million in Q1 2021, a decrease of 57% [14] - Operating cash burn for Q1 2022 was $7.8 million, down from $15.3 million in Q1 2021, a decrease of 49% [14] - As of March 2022, the company had approximately $68.3 million in cash and cash equivalents, with an anticipated cash runway into Q2 2023 [14] Business Line Data and Key Metrics Changes - The company is advancing its TCR-T Library trial, which targets hotspot mutations across six solid tumor indications, including non-small cell lung cancer and colorectal cancer [6][7] - The first patient in the Phase 1/2 TCR-T Library trial was successfully dosed, and the patient has cleared the 28-day safety window [8][10] - Approximately 500 lung or colorectal patients have been screened, with over 5% matching one of the TCRs in the library [9] Market Data and Key Metrics Changes - The company is collaborating with MD Anderson Cancer Center for patient enrollment and treatment in the TCR-T Library trial [7] - The trial design allows for the potential dosing of multiple patients at different dose levels based on Bayesian design principles [17] Company Strategy and Development Direction - Alaunos is focused on expanding its manufacturing capabilities through a three-pronged strategy, including implementing SOPs for simultaneous production, hiring additional staff, and investigating physical expansion of its cGMP footprint [9] - The company aims to file an IND for its membrane bound IL-15 program in the second half of 2023, indicating a commitment to advancing its R&D pipeline [11] - The company has realigned its Scientific Advisory Board with key opinion leaders in TCR-T cell therapy to guide its strategic direction [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to manage capital effectively and maximize shareholder value despite challenging market conditions [15] - The company has reduced its expected operating cash flow for 2022 to between $40 million and $45 million, reflecting a strategic restructuring completed last year [15] - Management emphasized the importance of safety in the early stages of the TCR-T Library trial and the need for continuous learning as the trial progresses [20] Other Important Information - The company plans to present initial data from the TCR-T Library trial at a major medical meeting in the second half of 2022 [10] - Alaunos is actively working on expanding its TCR library and enhancing its research capabilities using its proprietary hunTR platform [11][30] Q&A Session Summary Question: How many patients need to be enrolled to complete the TCR-T Phase 1/2 study? - Management indicated that the number of patients would depend on the dose levels and the information gained from treating patients with different indications, estimating around 10 to 15 patients for early Phase 1a [17][18] Question: How does the logistics work for patient identification and dosing? - Management explained that they work closely with MD Anderson to identify patients at the appropriate time, considering that many patients are at different stages of their disease [21] Question: What needs to be done before filing the IND for the membrane bound IL-15 program? - Management noted that manufacturing runs and regulatory strategy need to be completed, with preclinical data being encouraging [22][23] Question: How many patients can be treated per month with the current GMP facility? - Management stated that they would provide updates on manufacturing capabilities as they execute their initiatives, emphasizing the learning curve associated with new hires [25][26] Question: What is the status of the patient pipeline? - Management expressed confidence in patient accrual from MD Anderson, highlighting the diversity of cancer types and potential patients for treatment [38]